MX2009006177A - Composiciones de acetaminofen que tienen efectos colaterales minimizados incluyendo lepatotoxicidad reducida. - Google Patents
Composiciones de acetaminofen que tienen efectos colaterales minimizados incluyendo lepatotoxicidad reducida.Info
- Publication number
- MX2009006177A MX2009006177A MX2009006177A MX2009006177A MX2009006177A MX 2009006177 A MX2009006177 A MX 2009006177A MX 2009006177 A MX2009006177 A MX 2009006177A MX 2009006177 A MX2009006177 A MX 2009006177A MX 2009006177 A MX2009006177 A MX 2009006177A
- Authority
- MX
- Mexico
- Prior art keywords
- side effects
- effects including
- including reduced
- acetaminophen
- minimized side
- Prior art date
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title abstract 6
- 229960005489 paracetamol Drugs 0.000 title abstract 3
- 206010019851 Hepatotoxicity Diseases 0.000 title abstract 2
- 230000007686 hepatotoxicity Effects 0.000 title abstract 2
- 231100000304 hepatotoxicity Toxicity 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract 2
- 108010024636 Glutathione Proteins 0.000 abstract 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 230000003474 anti-emetic effect Effects 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 239000002111 antiemetic agent Substances 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 229960003180 glutathione Drugs 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 239000000932 sedative agent Substances 0.000 abstract 1
- 230000001624 sedative effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87374306P | 2006-12-09 | 2006-12-09 | |
| US11/952,556 US20080139654A1 (en) | 2006-12-09 | 2007-12-07 | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity |
| PCT/US2007/025167 WO2008073344A1 (en) | 2006-12-09 | 2007-12-08 | Acetaminophen compositions having minimized side effects including reduced hepatotoxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009006177A true MX2009006177A (es) | 2009-08-31 |
Family
ID=39498949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009006177A MX2009006177A (es) | 2006-12-09 | 2007-12-08 | Composiciones de acetaminofen que tienen efectos colaterales minimizados incluyendo lepatotoxicidad reducida. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080139654A1 (enExample) |
| EP (1) | EP2094253A4 (enExample) |
| JP (1) | JP2010513229A (enExample) |
| KR (1) | KR20090089867A (enExample) |
| CN (1) | CN101588797A (enExample) |
| AU (1) | AU2007332812A1 (enExample) |
| BR (1) | BRPI0721216A2 (enExample) |
| CA (1) | CA2671490A1 (enExample) |
| EA (1) | EA200970449A1 (enExample) |
| IL (1) | IL199056A0 (enExample) |
| MX (1) | MX2009006177A (enExample) |
| WO (1) | WO2008073344A1 (enExample) |
| ZA (1) | ZA200904764B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20080187A1 (it) * | 2008-02-07 | 2009-08-08 | Velleja Res Srl | Formulazioni di amminoacidi per la prevenzione del danno epatico da paracetamolo |
| CN102573463A (zh) * | 2009-07-15 | 2012-07-11 | 小利兰·斯坦福大学托管委员会 | N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法 |
| TR201007652A2 (tr) * | 2010-09-20 | 2012-04-24 | Bi̇lgi̇ç Mahmut | Sinerjik etki. |
| US20140235730A1 (en) * | 2011-09-23 | 2014-08-21 | Gavis Pharmaceuticals, Llc | Solid, edible, chewable laxative composition |
| WO2014159994A1 (en) * | 2013-03-13 | 2014-10-02 | Nbip, Llc | Compositions and methods for removing the odor from glutathione when mixed in an aqueous system |
| US10104882B2 (en) * | 2013-04-29 | 2018-10-23 | Montefiore Medical Center | Methods and compositions for preventing and treating electrophile-mediated toxicities |
| ITMI20130874A1 (it) * | 2013-05-29 | 2014-11-30 | Zambon Spa | Compresse deglutibili di n-acetilcisteina |
| JP7311267B2 (ja) * | 2016-01-11 | 2023-07-19 | エゲティス・セラピューティクス・アーベー | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 |
| KR101962518B1 (ko) | 2016-09-13 | 2019-03-26 | 울산대학교 산학협력단 | 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 함유하는 아세트아미노펜 유도 간 독성 예방 또는 치료용 조성물 |
| WO2018089400A1 (en) * | 2016-11-09 | 2018-05-17 | The Feinstein Institute For Medical Research | Iguratimod as an mif inhibitor |
| KR102813413B1 (ko) | 2019-08-27 | 2025-05-27 | 주식회사 엘지에너지솔루션 | 단위셀의 두께측정장치 및 두께측정방법 |
| US11590090B2 (en) | 2019-09-14 | 2023-02-28 | Anzen Pharmaceuticals, LLC | Acetaminophen formulation with protection against toxic effects of overdose |
| EP4238559A1 (en) | 2022-03-04 | 2023-09-06 | Centre Hospitalier Universitaire de Caen Normandie | Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474757A (en) * | 1992-10-16 | 1995-12-12 | Rutgers University | Prevention of acetaminophen overdose toxicity with organosulfur compounds |
| GR1002731B (el) * | 1996-10-21 | 1997-07-04 | Uni-Pharma ����� ������ �.�.�.�. ������������ ���������� | Φαρμακευτικα ενεσιμα διαλυματα περιεχοντα συνδυασμους παρακεταμολης με αλλες δραστικες ουσιες. |
| DE19651551C2 (de) * | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioidantagonisthaltige galenische Formulierung |
| US6566401B2 (en) * | 2001-03-30 | 2003-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity |
| US6863901B2 (en) * | 2001-11-30 | 2005-03-08 | Collegium Pharmaceutical, Inc. | Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration |
-
2007
- 2007-12-07 US US11/952,556 patent/US20080139654A1/en not_active Abandoned
- 2007-12-08 WO PCT/US2007/025167 patent/WO2008073344A1/en not_active Ceased
- 2007-12-08 BR BRPI0721216-0A2A patent/BRPI0721216A2/pt not_active Application Discontinuation
- 2007-12-08 EA EA200970449A patent/EA200970449A1/ru unknown
- 2007-12-08 JP JP2009540327A patent/JP2010513229A/ja not_active Withdrawn
- 2007-12-08 CN CNA2007800389520A patent/CN101588797A/zh active Pending
- 2007-12-08 AU AU2007332812A patent/AU2007332812A1/en not_active Abandoned
- 2007-12-08 KR KR1020097011839A patent/KR20090089867A/ko not_active Withdrawn
- 2007-12-08 CA CA002671490A patent/CA2671490A1/en not_active Abandoned
- 2007-12-08 MX MX2009006177A patent/MX2009006177A/es not_active Application Discontinuation
- 2007-12-08 EP EP07853309A patent/EP2094253A4/en not_active Withdrawn
-
2009
- 2009-06-01 IL IL199056A patent/IL199056A0/en unknown
- 2009-07-07 ZA ZA2009/04764A patent/ZA200904764B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA200970449A1 (ru) | 2009-08-28 |
| WO2008073344A1 (en) | 2008-06-19 |
| ZA200904764B (en) | 2012-12-27 |
| EP2094253A4 (en) | 2010-02-10 |
| BRPI0721216A2 (pt) | 2014-12-02 |
| AU2007332812A1 (en) | 2008-06-19 |
| US20080139654A1 (en) | 2008-06-12 |
| EP2094253A1 (en) | 2009-09-02 |
| CA2671490A1 (en) | 2008-06-19 |
| KR20090089867A (ko) | 2009-08-24 |
| IL199056A0 (en) | 2010-03-28 |
| CN101588797A (zh) | 2009-11-25 |
| JP2010513229A (ja) | 2010-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200970449A1 (ru) | Композиции ацетаминофена, обладающие сведенными к минимуму побочными эффектами, включая пониженную гепатотоксичность | |
| IL185626A0 (en) | Sublingual coated tablet | |
| WO2008063671A3 (en) | Heterobicyclic metalloprotease inhibitors | |
| MX2008015731A (es) | Tabletas sublinguales de baja dosificacion de analgesicos opiaiceos y proceso de preparacion. | |
| TNSN08178A1 (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
| PH12012501811A1 (en) | A solid pharmaceutical dosage formulation | |
| WO2007139856A3 (en) | Heterobicyclic metalloprotease inhibitors | |
| WO2007125547A3 (en) | Novel process for statins and its pharmaceutically acceptable salts thereof | |
| WO2008064353A3 (en) | 7,8-saturated-4,5-epoxy-morphinanium analogs | |
| MX2010006738A (es) | Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos. | |
| MX2010006736A (es) | Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos. | |
| WO2007139860A3 (en) | Heterobicylic metalloprotease inhibitors | |
| TW200833370A (en) | Pharmaceutical composition containing low substituted hydroxypropylcellulose | |
| TNSN08191A1 (en) | Kinase inhibitors | |
| ZA200810640B (en) | 1,5 -Diphenylpyrazoles II as HSP90 Inhibitors | |
| ZA200806778B (en) | N-Hydroxyacrylamide compounds | |
| WO2011140527A3 (en) | Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase | |
| MX2009011999A (es) | Extruidos con enmascaramiento del sabor mejorado. | |
| UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
| MX2010003591A (es) | Capa protectora mecanica para formas de dosificacion solidas. | |
| GB2456096A (en) | Crystalline form of benzothiophene compound and process for preparation thereof | |
| WO2008015584A3 (en) | Improved process for synthesizing desvenlafaxine free base and salts or solvates thereof | |
| MX2010010876A (es) | Piperidinas sustituidas como compuestos terapeuticos. | |
| MX2010006995A (es) | 3-n-fenil-1,3,4-oxadiazolonas sustituidas con 5-o para uso medico. | |
| BRPI0509014A (pt) | comprimidos desintegráveis que compreendem licarbazepina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |